Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$13.20
-0.45 (-3.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-85.9M · quality 72.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$876M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-64.3%
↓Gross Margin
80.3%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+52.7%
FCF CAGR
—
FCF margin
-25448.3%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $381000.0 · net income $-101.5M · FCF $-97.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $381000.00 | $381000.00 | — | $43000.00 | $107000.00 |
| Net Income | $-101.5M | $-101.5M | $-75.0M | $-59.7M | $-40.3M |
| EBITDA | $-92.1M | $-92.1M | $-65.7M | $-49.8M | $-31.1M |
| EPS | — | — | -1.14 | -1.21 | -0.86 |
| Gross Margin | 80.3% | 80.3% | — | 81.4% | 88.8% |
| Operating Margin | -27453.0% | -27453.0% | — | -137818.6% | -37547.7% |
| Net Margin | -26643.0% | -26643.0% | — | -138746.5% | -37642.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.05 | 0.05 | 0.29 |
| Current Ratio | 9.74 | 9.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-97.0M | $-97.0M | $-85.9M | $-27.8M | $-30.9M |
| Returns | |||||
| ROE | -64.3% | -64.3% | -29.4% | -18.3% | -58.2% |
| Valuation | |||||
| P/B | — | — | 3.00 | — | — |
| Growth & Yield | |||||
| Revenue Growth | — | — | — | -59.8% | — |
| EPS Growth | — | — | 5.8% | -40.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.14 → n/d
Residual
+10.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.